Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase 1 18Phase 1/2 7Phase 3 5Phase NA 3Phase 2/3 1

Status

Completed 5Recruiting 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 1

Conditions

Kidney Neoplasms 3Carcinoma, Renal Cell 2Neoplasms 1Kidney Diseases 1Carcinoma, Pancreatic Ductal 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Completed × Axitinib × Clear all
NCT02853331 2026-02-02

KEYNOTE-426

Merck Sharp & Dohme LLC

Phase 3 Completed
861 enrolled 24 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT00920816 2022-05-06

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Pfizer

Phase 3 Completed
492 enrolled 17 charts
Genitourinary

Kidney Neoplasms

NCT00678392 2019-01-09

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Pfizer

Phase 3 Completed
723 enrolled 15 charts
Genitourinary

Kidney Neoplasms

NCT00471146 2012-07-16

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Pfizer

Phase 3 Completed
630 enrolled 13 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡